Consideration of disease penetrance in the selection of secondary findings gene-disease pairs: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
作者信息
Gordon Adam S, Lee Kristy, Abul-Husn Noura S, Amendola Laura M, Brothers Kyle, Chung Wendy K, Gollob Michael H, Harrison Steven M, Hershberger Ray E, Richards C Sue, Stewart Douglas R, Martin Christa Lese, Miller David T
机构信息
Department of Pharmacology, Center for Genetic Medicine, Northwestern University, Chicago, IL.
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC.
出版信息
Genet Med. 2024 Jul;26(7):101142. doi: 10.1016/j.gim.2024.101142. Epub 2024 May 31.
Abstract
摘要
相似文献
1
Consideration of disease penetrance in the selection of secondary findings gene-disease pairs: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2024 Jul;26(7):101142. doi: 10.1016/j.gim.2024.101142. Epub 2024 May 31.
2
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2021 Aug;23(8):1391-1398. doi: 10.1038/s41436-021-01171-4. Epub 2021 May 20.
3
The use of ACMG secondary findings recommendations for general population screening: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2019 Jul;21(7):1467-1468. doi: 10.1038/s41436-019-0502-5. Epub 2019 Apr 25.
4
Points to consider in the reevaluation and reanalysis of genomic test results: a statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2019 Jun;21(6):1267-1270. doi: 10.1038/s41436-019-0478-1. Epub 2019 Apr 24.
5
ACMG SF v3.1 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2022 Jul;24(7):1407-1414. doi: 10.1016/j.gim.2022.04.006. Epub 2022 Jun 17.
6
Patient re-contact after revision of genomic test results: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2019 Apr;21(4):769-771. doi: 10.1038/s41436-018-0391-z. Epub 2018 Dec 22.
7
Pediatric clinical exome/genome sequencing and the engagement process: encouraging active conversation with the older child and adolescent: points to consider-a statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2018 Jul;20(7):692-694. doi: 10.1038/gim.2018.36. Epub 2018 Mar 22.
8
ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2023 Aug;25(8):100866. doi: 10.1016/j.gim.2023.100866. Epub 2023 Jun 22.
9
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2016 update (ACMG SF v2.0): a policy statement of the American College of Medical Genetics and Genomics.
Genet Med. 2017 Feb;19(2):249-255. doi: 10.1038/gim.2016.190. Epub 2016 Nov 17.
10
ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2025 Aug;27(8):101454. doi: 10.1016/j.gim.2025.101454. Epub 2025 Jun 23.
引用本文的文献
1
Detecting likely germline variants during tumor-based molecular profiling.
J Clin Invest. 2025 Aug 1;135(15). doi: 10.1172/JCI190264.
2
Incidental findings related to genes associated to HAE-nC1INH: how to proceed?
Front Immunol. 2025 Jun 17;16:1605727. doi: 10.3389/fimmu.2025.1605727. eCollection 2025.
3
ACMG SF v3.3 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2025 Aug;27(8):101454. doi: 10.1016/j.gim.2025.101454. Epub 2025 Jun 23.
4
Using large-scale population-based data to improve disease risk assessment of clinical variants.
Nat Genet. 2025 Jun 23. doi: 10.1038/s41588-025-02212-3.
5
2024 ASHG presidential address: Incomplete penetrance and variable expressivity: Old concepts, new urgency.
Am J Hum Genet. 2025 Mar 6;112(3):461-466. doi: 10.1016/j.ajhg.2025.01.010.
6
Re-envisioning genetic predisposition to childhood and adolescent cancers.
Nat Rev Cancer. 2025 Feb;25(2):109-128. doi: 10.1038/s41568-024-00775-7. Epub 2024 Dec 3.
本文引用的文献
1
Recommendations for risk allele evidence curation, classification, and reporting from the ClinGen Low Penetrance/Risk Allele Working Group.
Genet Med. 2024 Mar;26(3):101036. doi: 10.1016/j.gim.2023.101036. Epub 2023 Dec 3.
2
ACMG SF v3.2 list for reporting of secondary findings in clinical exome and genome sequencing: A policy statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2023 Aug;25(8):100866. doi: 10.1016/j.gim.2023.100866. Epub 2023 Jun 22.
3
Population-Based Penetrance of Deleterious Clinical Variants.
JAMA. 2022 Jan 25;327(4):350-359. doi: 10.1001/jama.2021.23686.
4
Penetrance of Breast Cancer Susceptibility Genes From the eMERGE III Network.
JNCI Cancer Spectr. 2021 May 8;5(4). doi: 10.1093/jncics/pkab044. eCollection 2021 Aug.
5
Recommendations for reporting of secondary findings in clinical exome and genome sequencing, 2021 update: a policy statement of the American College of Medical Genetics and Genomics (ACMG).
Genet Med. 2021 Aug;23(8):1391-1398. doi: 10.1038/s41436-021-01171-4. Epub 2021 May 20.
6
A genotype-first approach to exploring Mendelian cardiovascular traits with clear external manifestations.
Genet Med. 2021 Jan;23(1):94-102. doi: 10.1038/s41436-020-00973-2. Epub 2020 Sep 29.
7
Mastering genomic terminology.
Genet Med. 2017 May;19(5):491-492. doi: 10.1038/gim.2016.139. Epub 2016 Sep 22.
8
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing.
Genet Med. 2013 Jul;15(7):565-74. doi: 10.1038/gim.2013.73. Epub 2013 Jun 20.
Zotero 插件